- Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said Thursday its CFO Mardi Dier will step down , effective Nov. 15, to assume the dual role of CFO and chief business development officer at private biopharmaceutical firm ACELYRIN.
- Ultragenyx ( RARE ) said Ted Huizenga, chief accounting officer, and Aaron Olsen, SVP of corporate strategy and finance, will lead finance activities during the search for a new CFO.
- Dier will remain available to Ultragenyx ( RARE ) through the end of the year.
For further details see:
Ultragenyx Pharmaceutical CFO Mardi Dier to step down